{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:08:13Z","timestamp":1767006493107},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since 2013, the outbreak or sporadic infection of a new reassortant H7N9 influenza virus in China has resulted in hundreds of deaths and thousands of illnesses. An H7N9 vaccine is urgently needed, as a licensed human vaccine against H7N9 influenza is currently not available. Here, we developed a recombinant adenovirus-based vaccine, AdC68-H7HA, by cloning the H7N9 haemagglutinin (HA) gene into the chimpanzee adenoviral vector AdC68. The efficacy of AdC68-H7HA was evaluated in mice as well as guinea pigs. For comparison, an H7N9 DNA vaccine based on HA was also generated and tested in mice and guinea pigs. The results demonstrated that both AdC68-H7HA and the DNA vaccine prime-adenovirus boost regimen induced potent immune responses in animals and completely protected mice from lethal H7N9 influenza viral challenge. A post-immunization serum transfer experiment showed that antibody responses could completely protect against lethal challenge, while a T cell depletion experiment indicated that HA-specific CD8<jats:sup>+<\/jats:sup>T cells responses also contributed to protection. Therefore, both HA-specific humoral immunity and cellular immunity play important roles in the protection. These data suggest that the chimpanzee adenovirus expressing HA is a promising vaccine candidate for H7N9 virus or other influenza viral subtypes.<\/jats:p>","DOI":"10.1038\/s41598-017-02019-1","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T11:14:30Z","timestamp":1494242070000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge"],"prefix":"10.1038","volume":"7","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songhua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudan","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"2019_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-med-010714-112311","volume":"66","author":"DB Jernigan","year":"2015","unstructured":"Jernigan, D. B. & Cox, N. J. H7N9: preparing for the unexpected in influenza. Annu Rev Med 66, 361\u2013371, doi:10.1146\/annurev-med-010714-112311 (2015).","journal-title":"Annu Rev Med"},{"key":"2019_CR2","doi-asserted-by":"publisher","first-page":"8671","DOI":"10.1128\/JVI.01034-15","volume":"89","author":"S Su","year":"2015","unstructured":"Su, S. et al. Epidemiology, Evolution, and Recent Outbreaks of Avian Influenza Virus in China. J Virol 89, 8671\u20138676, doi:10.1128\/JVI.01034-15 (2015).","journal-title":"J Virol"},{"key":"2019_CR3","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","volume":"368","author":"R Gao","year":"2013","unstructured":"Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. The New England journal of medicine 368, 1888\u20131897, doi:10.1056\/NEJMoa1304459 (2013).","journal-title":"The New England journal of medicine"},{"key":"2019_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3201\/eid1506.090072","volume":"15","author":"JA Belser","year":"2009","unstructured":"Belser, J. A., Bridges, C. B., Katz, J. M. & Tumpey, T. M. Past, present, and possible future human infection with influenza virus A subtype H7. Emerging infectious diseases 15, 859\u2013865, doi:10.3201\/eid1506.090072 (2009).","journal-title":"Emerging infectious diseases"},{"key":"2019_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2015-3279","volume":"137","author":"JR Chung","year":"2016","unstructured":"Chung, J. R. et al. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics 137, 1\u201310, doi:10.1542\/peds.2015-3279 (2016).","journal-title":"Pediatrics"},{"key":"2019_CR6","doi-asserted-by":"publisher","unstructured":"Osterholm, M. T., Kelley, N. S., Sommer, A. & Belongia, E. A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet. Infectious diseases 12, 36\u201344, doi:10.1016\/S1473-3099(11)70295-X (2012).","DOI":"10.1016\/S1473-3099(11)70295-X"},{"issue":"Suppl 4","key":"2019_CR7","doi-asserted-by":"publisher","first-page":"D10","DOI":"10.1016\/j.vaccine.2008.06.083","volume":"26","author":"RB Belshe","year":"2008","unstructured":"Belshe, R. B., Ambrose, C. S. & Yi, T. Safety and efficacy of live attenuated influenza vaccine in children 2\u20137 years of age. Vaccine 26(Suppl 4), D10\u201316, doi:10.1016\/j.vaccine.2008.06.083 (2008).","journal-title":"Vaccine"},{"key":"2019_CR8","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1016\/j.vaccine.2008.07.013","volume":"26","author":"SL Block","year":"2008","unstructured":"Block, S. L. et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5\u201349 years of age. Vaccine 26, 4940\u20134946, doi:10.1016\/j.vaccine.2008.07.013 (2008).","journal-title":"Vaccine"},{"key":"2019_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12052-011-0365-y","volume":"4","author":"KA Hanley","year":"2011","unstructured":"Hanley, K. A. The double-edged sword: How evolution can make or break a live-attenuated virus vaccine. Evolution (N Y) 4, 635\u2013643, doi:10.1007\/s12052-011-0365-y (2011).","journal-title":"Evolution (N Y)"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature12379","volume":"499","author":"J Zhou","year":"2013","unstructured":"Zhou, J. et al. Biological features of novel avian influenza A (H7N9) virus. Nature 499, 500\u2013503, doi:10.1038\/nature12379 (2013).","journal-title":"Nature"},{"key":"2019_CR11","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1016\/j.vaccine.2007.07.027","volume":"25","author":"F Carrat","year":"2007","unstructured":"Carrat, F. & Flahault, A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25, 6852\u20136862, doi:10.1016\/j.vaccine.2007.07.027 (2007).","journal-title":"Vaccine"},{"key":"2019_CR12","doi-asserted-by":"publisher","first-page":"e99322","DOI":"10.1371\/journal.pone.0099322","volume":"9","author":"Y Duan","year":"2014","unstructured":"Duan, Y. et al. Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine. PloS one 9, e99322, doi:10.1371\/journal.pone.0099322 (2014).","journal-title":"PloS one"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"11233","DOI":"10.1038\/srep11233","volume":"5","author":"H Kong","year":"2015","unstructured":"Kong, H. et al. A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals. Scientific reports 5, 11233, doi:10.1038\/srep11233 (2015).","journal-title":"Scientific reports"},{"key":"2019_CR14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8596","author":"M Xing","year":"2016","unstructured":"Xing, M., Wang, X., Chi, Y. & Zhou, D. Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. Oncotarget. doi:10.18632\/oncotarget.8596 (2016).","journal-title":"Oncotarget"},{"key":"2019_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/jmv.23546","volume":"85","author":"S Zhang","year":"2013","unstructured":"Zhang, S. et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. Journal of medical virology 85, 1077\u20131084, doi:10.1002\/jmv.23546 (2013).","journal-title":"Journal of medical virology"},{"key":"2019_CR16","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1038\/mtna.2016.25","volume":"5","author":"X Tang","year":"2016","unstructured":"Tang, X., Zhang, H., Song, Y., Zhou, D. & Wang, J. Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection. Molecular therapy. Nucleic acids 5, e311, doi:10.1038\/mtna.2016.25 (2016).","journal-title":"Molecular therapy. Nucleic acids"},{"key":"2019_CR17","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1016\/j.vaccine.2015.08.016","volume":"33","author":"C Zhang","year":"2015","unstructured":"Zhang, C. et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71. Vaccine 33, 5087\u20135094, doi:10.1016\/j.vaccine.2015.08.016 (2015).","journal-title":"Vaccine"},{"key":"2019_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/mt.2012.248","volume":"21","author":"DM Zhou","year":"2013","unstructured":"Zhou, D. M. et al. Hexon-modified Recombinant E1-deleted Adenovirus Vectors as Dual Specificity Vaccine Carriers for Influenza Virus. Molecular Therapy 21, 696\u2013706, doi:10.1038\/mt.2012.248 (2013).","journal-title":"Molecular Therapy"},{"key":"2019_CR19","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ymthe.2006.03.027","volume":"14","author":"DM Zhou","year":"2006","unstructured":"Zhou, D. M., Cun, A., Li, Y., Xiang, Z. Q. & Ertl, H. C. J. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Molecular Therapy 14, 662\u2013672, doi:10.1016\/j.ymthe.2006.03.027 (2006).","journal-title":"Molecular Therapy"},{"key":"2019_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","volume":"69","author":"JJ Skehel","year":"2000","unstructured":"Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual review of biochemistry 69, 531\u2013569, doi:10.1146\/annurev.biochem.69.1.531 (2000).","journal-title":"Annual review of biochemistry"},{"key":"2019_CR21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1128\/jvi.63.3.1239-1246.1989","volume":"63","author":"BE Johansson","year":"1989","unstructured":"Johansson, B. E., Bucher, D. J. & Kilbourne, E. D. Purified Influenza-Virus Hemagglutinin and Neuraminidase Are Equivalent in Stimulation of Antibody-Response but Induce Contrasting Types of Immunity to Infection. Journal of virology 63, 1239\u20131246 (1989).","journal-title":"Journal of virology"},{"key":"2019_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2146\/news130016","volume":"70","author":"K Traynor","year":"2013","unstructured":"Traynor, K. First recombinant flu vaccine approved. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 70, 382, doi:10.2146\/news130016 (2013).","journal-title":"American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists"},{"key":"2019_CR23","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.3390\/v7082821","volume":"7","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB\/C Mice. Viruses 7, 4369\u20134384, doi:10.3390\/v7082821 (2015).","journal-title":"Viruses"},{"key":"2019_CR24","doi-asserted-by":"publisher","unstructured":"Hu, Y. W. et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381, 2273\u20132279, doi:10.1016\/S0140-6736(13)61125-3 (2013).","DOI":"10.1016\/S0140-6736(13)61125-3"},{"key":"2019_CR25","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1128\/AAC.00793-15","volume":"59","author":"Y Itoh","year":"2015","unstructured":"Itoh, Y. et al. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. Antimicrobial agents and chemotherapy 59, 4962\u20134973, doi:10.1128\/AAC.00793-15 (2015).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"2019_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jgm.2698","volume":"15","author":"SL Ginn","year":"2013","unstructured":"Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R. & Wixon, J. Gene therapy clinical trials worldwide to 2012 an update. Journal of Gene Medicine 15, 65\u201377, doi:10.1002\/jgm.2698 (2013).","journal-title":"Journal of Gene Medicine"},{"key":"2019_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/infdis\/jiu528","volume":"211","author":"JH Kreijtz","year":"2015","unstructured":"Kreijtz, J. H. et al. A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. The Journal of infectious diseases 211, 791\u2013800, doi:10.1093\/infdis\/jiu528 (2015).","journal-title":"The Journal of infectious diseases"},{"key":"2019_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.vaccine.2015.12.062","volume":"34","author":"W Cao","year":"2016","unstructured":"Cao, W. et al. A highly immunogenic vaccine against A\/H7N9 influenza virus. Vaccine 34, 744\u2013749, doi:10.1016\/j.vaccine.2015.12.062 (2016).","journal-title":"Vaccine"},{"key":"2019_CR29","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1038\/emi.2014.30","volume":"3","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infect 3, e30, doi:10.1038\/emi.2014.30 (2014).","journal-title":"Emerg Microbes Infect"},{"key":"2019_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.08.066","author":"T Cheng","year":"2016","unstructured":"Cheng, T. et al. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1. Vaccine. doi:10.1016\/j.vaccine.2016.08.066 (2016).","journal-title":"Vaccine"},{"key":"2019_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/sj.gt.3302675","volume":"13","author":"N Tatsis","year":"2006","unstructured":"Tatsis, N. et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene therapy 13, 421\u2013429, doi:10.1038\/sj.gt.3302675 (2006).","journal-title":"Gene therapy"},{"key":"2019_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","volume":"83","author":"CJ Cohen","year":"2002","unstructured":"Cohen, C. J. et al. Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 83, 151\u2013155 (2002).","journal-title":"J Gen Virol"},{"key":"2019_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erv.11.188","volume":"11","author":"F Saade","year":"2012","unstructured":"Saade, F. & Petrovsky, N. Technologies for enhanced efficacy of DNA vaccines. Expert review of vaccines 11, 189\u2013209, doi:10.1586\/erv.11.188 (2012).","journal-title":"Expert review of vaccines"},{"key":"2019_CR34","doi-asserted-by":"crossref","unstructured":"Wang, Z. F. et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells. Nat Commun 6, doi:Artn 6833 10.1038\/Ncomms7833 (2015).","DOI":"10.1038\/ncomms7833"},{"key":"2019_CR35","doi-asserted-by":"crossref","unstructured":"Xu, J. Q. Rapid recovery from severe H7N9 disease requires a diversity of response mechanisms driven by CD8(+) T cells. J Immunol 194 (2015).","DOI":"10.4049\/jimmunol.194.Supp.75.1"},{"key":"2019_CR36","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.1128\/JVI.00976-15","volume":"89","author":"YF Song","year":"2015","unstructured":"Song, Y. F. et al. Repeated Low-Dose Influenza Virus Infection Causes Severe Disease in Mice: a Model for Vaccine Evaluation. Journal of virology 89, 7841\u20137851, doi:10.1128\/JVI.00976-15 (2015).","journal-title":"Journal of virology"},{"key":"2019_CR37","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3201\/eid1910.130728","volume":"19","author":"C Qiu","year":"2013","unstructured":"Qiu, C. et al. Safe pseudovirus-based assay for neutralization antibodies against influenza A(H7N9) virus. Emerging infectious diseases 19, 1685\u20131687, doi:10.3201\/eid1910.130728 (2013).","journal-title":"Emerging infectious diseases"},{"key":"2019_CR38","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1128\/JVI.02611-10","volume":"85","author":"M Larena","year":"2011","unstructured":"Larena, M., Regner, M., Lee, E. & Lobigs, M. Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis. Journal of virology 85, 5446\u20135455, doi:10.1128\/JVI.02611-10 (2011).","journal-title":"Journal of virology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02019-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02019-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02019-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T13:09:26Z","timestamp":1692796166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02019-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-02019-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"assertion":[{"value":"16 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1854"}}